Drugs / PT2385
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02553356 | Sep → Nov 2015 | — | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT03216499 | Sep 2017 → Aug 2019 | glioblastoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PT2385 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02553356 ↗ |
| Known as | CPD 10I | ChEMBL registry synonym — accepted as the source's own label CHEMBL4173075 ↗ |
| Action | Inhibit | “PT2385 is an oral HIF2α inhibitor with in vivo activity against GBM.” PMID 37864646 ↗ Oct 2023 |
| Modality | Small molecule | — CHEMBL4173075 ↗ |
| Route | Oral | “Patients receive HIF-2 alpha inhibitor PT2385 orally (PO) twice daily (BID) on days 1-28.” NCT03216499 ↗ |